Novo Resources has completed the first tranche of a capital raising, securing A$6.2 million, while announcing significant valuation impairments ahead of its 2025 financial report.
- Completion of Tranche 1 placement raising ~A$6.2 million
- Issuance of ~8.4 million units in Canada and ~50.6 million CDIs outside Canada
- Valuation write-down of Elementum 3D investment by ~A$13.18 million
- Impairment of tenements valued at ~A$10.67 million
- Tranche 2 placement subject to shareholder approval at May 2026 AGM
Capital Raising Milestone
Mining and gold exploration company Novo Resources Corp (ASX: NVO) has successfully completed the first tranche of its recent placement, raising approximately C$5.9 million (around A$6.2 million). This tranche involved issuing roughly 8.4 million units to Canadian investors and about 50.6 million Chess Depository Interests (CDIs) to investors outside Canada. Each unit in Canada includes one common share and half a warrant, while each CDI represents one common share.
The company welcomed new shareholders through this placement and acknowledged the ongoing support of existing investors. However, the second tranche of the placement remains conditional on shareholder approval, expected to be sought at Novo’s Annual General Meeting slated for May 2026.
Significant Valuation Adjustments
Alongside the capital raising update, Novo disclosed a substantial valuation write-down related to its investment portfolio. The company will reduce the carrying value of its stake in Elementum 3D, a US-based 3D printing materials technology firm, by approximately C$12.84 million (A$13.18 million). This adjustment reflects updated market conditions and trading data as of the 31 December 2025 reporting period.
In addition, Novo will recognise an impairment of C$10.36 million (A$10.67 million) related to its mining tenements. This follows the sale or relinquishment of several tenements during the year and aligns with the company’s accounting policies to ensure asset values are appropriately recorded.
Looking Ahead
These valuation changes will be incorporated into Novo’s forthcoming financial report for the year ended 31 December 2025, expected to be released shortly. The impairments underscore the challenges of asset valuation in volatile markets and the company’s ongoing portfolio rationalisation efforts.
Investors will be watching closely how the second tranche of the placement unfolds post-AGM and how Novo navigates its asset base amid these write-downs. The capital injection from the placement provides some financial flexibility, but the valuation impairments highlight the risks inherent in exploration and technology investments.
Bottom Line?
Novo’s fresh capital boost comes with a stark reminder of the valuation risks ahead.
Questions in the middle?
- Will shareholder approval for Tranche 2 proceed smoothly at the May AGM?
- How will the valuation impairments impact Novo’s strategic priorities and exploration plans?
- What market factors drove the significant write-down of Elementum 3D’s value?